Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03521154 · OUTCOME

Proportion With Tumour Shrinkage by Blinded Independent Central Review (BICR)

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA) · Source last updated 2026-08-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Proportion of participants
Interval / dispersion
Not reported
Time frame
Every 8 weeks for first 48 weeks, then every 12 weeks until BICR-confirmed radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months

What was measured

Proportion with depth of response (or tumour shrinkage or change in tumour size)

Analysis population: Full analysis set

Groups in this outcome

Osimertinib

80mg once daily tablet

Placebo

Matching Placebo

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Osimertinib143
Placebo73

Reported measurements

Proportion with reduction
Values in Proportion of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Osimertinib0.92Not reportedNot reportedNot reportedNot reported
Placebo0.83Not reportedNot reportedNot reportedNot reported
Proportion with reduction > 30%
Values in Proportion of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Osimertinib0.65Not reportedNot reportedNot reportedNot reported
Placebo0.40Not reportedNot reportedNot reportedNot reported
Proportion with reduction > 50%
Values in Proportion of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Osimertinib0.43Not reportedNot reportedNot reportedNot reported
Placebo0.11Not reportedNot reportedNot reportedNot reported
Proportion with reduction > 75%
Values in Proportion of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Osimertinib0.18Not reportedNot reportedNot reportedNot reported
Placebo0.09Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0.92
      2. group Id
        OG001
        value
        0.83
    title
    Proportion with reduction
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        0.65
      2. group Id
        OG001
        value
        0.40
    title
    Proportion with reduction > 30%
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        0.43
      2. group Id
        OG001
        value
        0.11
    title
    Proportion with reduction > 50%
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        0.18
      2. group Id
        OG001
        value
        0.09
    title
    Proportion with reduction > 75%
denoms
  1. counts
    1. group Id
      OG000
      value
      143
    2. group Id
      OG001
      value
      73
    units
    Participants
description
Proportion with depth of response (or tumour shrinkage or change in tumour size)
groups
  1. description
    80mg once daily tablet
    id
    OG000
    title
    Osimertinib
  2. description
    Matching Placebo
    id
    OG001
    title
    Placebo
param Type
NUMBER
population Description
Full analysis set
reporting Status
POSTED
time Frame
Every 8 weeks for first 48 weeks, then every 12 weeks until BICR-confirmed radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months
title
Proportion With Tumour Shrinkage by Blinded Independent Central Review (BICR)
type
SECONDARY
unit Of Measure
Proportion of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice